Comprehensive analysis of etrasimod-related adverse events based on the FDA Adverse Event Reporting System database. [PDF]
Zhou ZR +5 more
europepmc +1 more source
Mechanisms and therapeutic opportunities of the ribotoxic stress response in cancer
Cancer cells' high translational demand creates opportunities to therapeutically target ribosome function. Ribosome stalling and collisions activate ZAKα and the ribotoxic stress response (RSR), which can trigger rapid, p53‐independent apoptosis in cancer.
Anastassiya Kim +7 more
wiley +1 more source
Job Problems in Suicide: National Violent Death Reporting System, 2020-2022. [PDF]
Tiesman HM +3 more
europepmc +1 more source
This study integrates publicly available transcriptomic datasets to identify molecular signatures associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. By analyzing a combination of multiple cohorts with bioinformatics approaches, we reveal biological pathways and immune‐related features that may improve ...
Aleksandra Stanojevic +10 more
wiley +1 more source
Neurological Adverse Events Associated With Immune Checkpoint Inhibitors Identified Through Disproportionality Analysis of the FDA Adverse Event Reporting System. [PDF]
Chen T +5 more
europepmc +1 more source
The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad +2 more
wiley +1 more source
Overcoming the curse of knowledge: guidelines for reporting system-specific details of host infection and migration dynamics. [PDF]
Binning SA, Shaw AK.
europepmc +1 more source
Risk factors for drug-related cachexia: an analysis based on the FDA adverse event reporting system (FAERS) from 2004 to 2025. [PDF]
Huang L, Dong S, Zhang Q, Ni J.
europepmc +1 more source
Real world pharmacovigilance study of FDA adverse event reporting system events for Spiriva Respimat. [PDF]
Chen K, Zhao S, Deng W, Ma Q, Xiao H.
europepmc +1 more source

